BTIG Downgrades Teva Pharma (TEVA) to Neutral
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
BTIG downgraded Teva Pharma (NYSE: TEVA) from Buy to Neutral and removed its price target. Analyst Timothy Chiang noted Copaxone risk.
"We downgrade TEVA shares to Neutral based on three key factors: 1) poor visibility on near term revenue growth drivers for the generic / branded segments, 2) heavy debt leverage (Teva has ~$36.9B of outstanding debt) which currently stands at ~5x debt/ebitda which provides the Co. little margin for error going forward, and 3) the potential for generic entry on Copaxone 40mg in 2017 – Copaxone remains a key contributor to the Co.’s sales (19% of total), and operating profits (42% of total). While Copaxone 40mg is protected by five Orange Book listed patents, we think a key US District (Delaware) Court decision is upcoming in early 2017. While the shares were down ~8% today, we think the near term risks outweigh any potential upside that might occur with this upcoming legal decision," said the analyst.
Shares of Teva Pharma closed at $37.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Pharma (TEVA) Loses Bid to Revive '413, '250, and Third Capaxone Patent in IPR Review - Bloomberg
- Jefferies Cuts Price Target on PG&E Corp. (PCG) to $65 Following Rate Case Decision
- Drexel Hamilton Raises Price Target on Workday (WDAY) Following 3Q Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!